Z

Zentalis Pharmaceuticals
D

ZNTL

1.54500
USD
-0.08
(-4.92%)
مغلق
حجم التداول
54,642
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
111,449,275
الأخبار المقالات

العنوان: Zentalis Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer(Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.